The significance of Serum Vitamin D Levels on Changes in Hematological Parameters After Chemotherapy in Patients with Breast Cancer

Objective: To investigate the relationship between serum Vitamin D (VD) level and the change of hematological parameters after chemotherapy in patients with breast cancer (BC) who received adjuvant Adriamycin and Cyclophosphamide (AC). Material and Methods: A total of 74 BC patients who were treated with adjuvant 60 mg/m2 Adriamycin and 600 mg/m2 Cyclophosphamide (AC) were included in the study. VD levels, complete blood count (CBC) findings after 1st cycle AC were retrospectively recorded. The relationship between changes in CBC parameters according to VD levels and the presence of hematological toxicity was examined. Results: The mean age was 55.11±9.97 years and the median VD level was 12.78 (4-53.40) ng/mL. In all patient groups, there was a significant decrease in the values of lymphocytes and monocytes after chemotherapy (p=0.030, p=0.024 respectively). In the correlation analysis, there was no correlation between VD levels and hemoglobin levels, the number of cells in CBC-1, and the amount of change in the number of cells in after chemotherapy. However, there was a negative correlation between VD level and platelet/lymphocyte ratio-1 (PLR-1), monocyte/lymphocyte ratio-1 (MLR-1) (p=0.025, r:-0.237; p=0.001, r:-0.370, respectively), but there was no correlation with PLR-2 and MLR-2 (p>0.05 all). Conclusion: There was no relationship between VD levels and changes in hematological parameters and hematological toxicity related to AC chemotherapy in the patient with BC. VD level was inversely correlated with PLR-1 and MLR-1, which is generally accepted as inflammatory markers. This result showed that the levels of VD do not have a significant role in the development of hematological toxicity after AC chemotherapy in BC.